The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy

  • Maeng, Chi Hoon (Division of Hematology and Oncology, Department of Internal Medicine, Kyung Hee University Medical Center) ;
  • Ahn, Sung Woo (Department of Education and Training, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Ryu, Seong-Yoon (Department of Education and Training, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Han, Sungjun (Department of Education and Training, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Ko, Young Hyeh (Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Ji, Jun Ho (Division of Hematology and Oncology, Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine) ;
  • Kim, Won Seog (Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kim, Seok Jin (Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • Received : 2014.07.24
  • Accepted : 2015.04.15
  • Published : 2016.05.01
⟨ Previous Next ⟩

Abstract

Background/Aims: The Follicular Lymphoma International Prognostic Index (FLIPI) and FLIPI2 are well-known prognostic models for patients with follicular lymphoma (FL). However, their prognostic relevance has not been examined before in Korean patients with FL. Methods: We reviewed clinical and laboratory information from our database of patients between 1995 and 2012. In total, 125 patients were stratified in three categories according to FLIPI or FLIPI2 scores: low-, intermediate-, and high-risk groups. We compared FLIPI and FLIPI2 in terms of progression-free survival (PFS) and overall survival (OS). Results: Among the 125 patients, the prognostic value of FLIPI and FLIPI2 was evaluated in 73 patients who fulfilled the criteria of both prognostic models. Risk stratification by FLIPI and FLIPI2 showed significant differences in unfavorable parameters among each risk group, particularly between low- and intermediate-risk groups. The high-risk group b was significantly associated with poor PFS on both FLIPI and FLIPI2 (p < 0.05). However, the OS was significantly different only in the risk groups determined by FLIPI2 (p = 0.042). In a subgroup analysis of patients who received rituximab-containing chemotherapy, the risk stratification of both prognostic models showed a significant impact on PFS, especially in the low-risk group. Conclusions: FLIPI and FLIPI2 are appropriate prognostic models in Korean FL patients, especially for discriminating low-risk patients from intermediate- and high-risk groups.

Keywords

References

  1. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006;107:265-276. https://doi.org/10.1182/blood-2005-06-2508
  2. Huh J. Epidemiologic overview of malignant lymphoma. Korean J Hematol 2012;47:92-104. https://doi.org/10.5045/kjh.2012.47.2.92
  3. Park HJ, Park EH, Jung KW, et al. Statistics of hematologic malignancies in Korea: incidence, prevalence and survival rates from 1999 to 2008. Korean J Hematol 2012;47:28-38. https://doi.org/10.5045/kjh.2012.47.1.28
  4. Tan D, Horning SJ. Follicular lymphoma: clinical features and treatment. Hematol Oncol Clin North Am 2008;22:863-882. https://doi.org/10.1016/j.hoc.2008.07.013
  5. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-994. https://doi.org/10.1056/NEJM199309303291402
  6. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-1265. https://doi.org/10.1182/blood-2003-12-4434
  7. Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009;27:4555-4562. https://doi.org/10.1200/JCO.2008.21.3991
  8. Arcaini L, Merli M, Passamonti F, et al. Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients. Br J Haematol 2010;149:455-457. https://doi.org/10.1111/j.1365-2141.2009.08065.x
  9. Swerdlow SH CE, Harris NL, et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2008.
  10. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997;89:3909-3918.
  11. Canioni D, Brice P, Lepage E, et al. Bone marrow histological patterns can predict survival of patients with grade 1 or 2 follicular lymphoma: a study from the Groupe d'Etude des Lymphomes Folliculaires. Br J Haematol 2004;126:364-371. https://doi.org/10.1111/j.1365-2141.2004.05046.x
  12. Pettengell R. Advanced-stage follicular lymphoma in the rituximab era: when should patients receive anthracycline-based chemotherapy? Drugs 2009;69:1727-1737. https://doi.org/10.2165/11317050-000000000-00000
  13. Formica V, Norman AR, Cunningham D, Wotherspoon A, Oates J, Chong G. Utility of the Follicular Lymphoma International Prognostic Index and the International Prognostic Index in assessing prognosis and predicting firstline treatment efficacy in follicular lymphoma patients. Acta Haematol 2009;122:193-199. https://doi.org/10.1159/000253026
  14. Luminari S, Cox MC, Montanini A, Federico M. Prognostic tools in follicular lymphomas. Expert Rev Hematol 2009;2:549-562. https://doi.org/10.1586/ehm.09.34
  15. Solal-Celigny P, Cahu X, Cartron G. Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful? Int J Hematol 2010;92:246-254. https://doi.org/10.1007/s12185-010-0674-x
  16. Van de Schans SA, Steyerberg EW, Nijziel MR, Creemers GJ, Janssen-Heijnen ML, van Spronsen DJ. Validation, revision and extension of the Follicular LymphomaInternational Prognostic Index (FLIPI) in a population-based setting. Ann Oncol 2009;20:1697-1702. https://doi.org/10.1093/annonc/mdp053
  17. Numata A, Tomita N, Fujimaki K, et al. Retrospective study of the utility of FLIPI/FLIPI-2 for follicular lymphoma patients treated with R-CHOP. J Clin Exp Hematop 2012;52:77-79. https://doi.org/10.3960/jslrt.52.77

Cited by

  1. Radiation Therapy Outcome and Clinical Features of Duodenal-Type Follicular Lymphoma vol.51, pp.2, 2016, https://doi.org/10.4143/crt.2018.190